QIAGEN (QGEN)
(Delayed Data from NYSE)
$43.73 USD
+0.56 (1.30%)
Updated May 24, 2024 04:00 PM ET
After-Market: $43.75 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.73 USD
+0.56 (1.30%)
Updated May 24, 2024 04:00 PM ET
After-Market: $43.75 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification
by Zacks Equity Research
QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.
QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus
by Zacks Equity Research
QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.
QIAGEN (QGEN) to Enhance Forensics With New Partnership
by Zacks Equity Research
QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.
International Markets and Qiagen (QGEN): A Deep Dive for Investors
by Zacks Equity Research
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Qiagen (QGEN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 4.55% and 0.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Qiagen (QGEN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches
by Zacks Equity Research
QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.
QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access
by Zacks Equity Research
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.
QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness
by Zacks Equity Research
QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
by Zacks Equity Research
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Qiagen (QGEN) Up 1.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base
by Zacks Equity Research
QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.
QIAGEN (QGEN) Earns Notable Recognitions in Sustainability
by Zacks Equity Research
QIAGEN (QGEN) achieves the ACT Label for new eco-friendly QIAwave products and the first My Green Lab Platinum certification.
QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands
by Zacks Equity Research
QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.
Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences
by Zacks Equity Research
QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.
QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay
by Zacks Equity Research
QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.
QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes
by Zacks Equity Research
QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.